GlobeNewswire

Mitratech Yields Accolades as Market Leader and Innovator by Analyst Firm Hyperion Research

Dela

Powerful "zero-code" product configuration, expansive user experience enhancements, and upgrades-included program set Mitratech's TeamConnect apart from other solution providers

AUSTIN, Texas, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Mitratech, a leading provider of legal, compliance, and risk management software solutions, today announced that its enterprise legal management (ELM) products have earned distinctions as Market Leaders and Highly Innovative products in the 2017 MarketView(TM) Report on Enterprise Legal Management by Hyperion Research, a leading analyst-based market research firm covering the ELM market.

Mitratech's years of investment in TeamConnect continues to deliver strong results - being one of the strongest products in the ELM market with top rankings across many of the rating categories in the MarketView(TM) Report. TeamConnect is the only ELM platform in the industry that includes code-free customizations, saving its clients significant time and money. And, its one-of-a-kind "upgrades-included" program demonstrates the company's true commitment to client success.

According to Hyperion, "TeamConnect, driven by aggressive development and a holistic vision of ELM in recent years, is one of the leading systems serving the enterprise market."1

"We are honored to be recognized as a Market Leader once again," said Mitratech CEO Jason Parkman. "We made the decision four years ago to pull ahead of all other ELM providers by offering something no one else can. It was a significant investment that is paying off for our clients today."

TeamConnect is one of three Mitratech products to make Hyperion's top ten and qualify as Advanced Solutions. Each Advanced Solution met all of Hyperion's Key Solution Components - fundamental requirements that define leading ELM practices for both e-billing and matter management. Twenty-three corporate legal department software products were evaluated with an opportunity to qualify for this distinction.

Hyperion validated Mitratech's vision to develop products that enable increased collaboration and communication between legal, compliance and risk professionals: "One of the things that distinguishes Mitratech from its competitors is its espoused worldview of ELM. Management contextualizes the discipline as part of a larger Governance, Risk and Compliance (GRC) universe, where risk management is perhaps as important as, or more important than, operational efficiency,"2 stated Hyperion.

Hyperion Research's MarketView(TM) report provides a comprehensive review of the broad market for Enterprise Legal Management technologies. The report provides a guidebook for ELM system evaluation, including market trends and dynamics, key components expected from leading solutions, an overview of vendors in the solution area, and guiding principles for selecting and implementing solutions.

The full report is available for download on the Hyperion website. For more information about Mitratech's products and services, visit www.mitratech.com.

ABOUT MITRATECH
Mitratech is a market-leading provider of legal, compliance, and risk software solutions for more than 1,200 organizations of all sizes across the globe, representing almost 40 percent of the Fortune 500, and over 500,000 users in over 160 countries. Mitratech's portfolio of enterprise legal and risk management software includes: legal matter management, spend management, e-Billing, legal hold, contracts management, risk management, policy management, audit management, and health & safety management. To learn more, visit www.mitratech.com.

ABOUT HYPERION RESEARCH
Hyperion Research is the industry's leading source for Legal Solutions Market Intelligence. We work with law firms, law departments and other legal service organizations to make intelligent, fact-based decisions about how to improve their operational performance. The profession's leaders, innovators and trend-makers have come to rely on Hyperion Research as the premier provider of independent market research, analysis and advisory services. We provide unparalleled insight to the leading trends in legal strategy, operations, and technology. Hyperion's analyst-based research and benchmarking informs 8 out of every 10 practice management system selections each year. For more information, visit www.hgpresearch.com.

__________________________________
1 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 100), Hyperion Research (elm.hgp-marketview.com).
2 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 101), Hyperion Research (elm.hgp-marketview.com).

Mitratech

Chris Kraft

512-382-7322




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mitratech via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum